CureVac gets OK to start testing mRNA COVID-19 vaccine in humans

CureVac has received regulatory clearance to start a phase 1 trial of its COVID-19 vaccine. The start of the 168-subject study comes days after the German government invested €300 million ($337 million) in CureVac to support its efforts to develop and manufacture a vaccine against the coronavirus.